WO2007091528A1 - 新規ジオクタチン誘導体及びその製造方法 - Google Patents
新規ジオクタチン誘導体及びその製造方法 Download PDFInfo
- Publication number
- WO2007091528A1 WO2007091528A1 PCT/JP2007/051949 JP2007051949W WO2007091528A1 WO 2007091528 A1 WO2007091528 A1 WO 2007091528A1 JP 2007051949 W JP2007051949 W JP 2007051949W WO 2007091528 A1 WO2007091528 A1 WO 2007091528A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- structural formula
- dioctatin
- derivative
- aflatoxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to a novel dioctatin derivative and a method for producing the same, and to an aflatoxin production inhibitor containing the novel dioctatin derivative, and further to a method for controlling aflatoxin contamination using the aflatoxin production inhibitor.
- Dioctatin is identified as a physiologically active substance that specifically inhibits dipeptidylaminopeptidase II (DPPII), and is a culture of dioctatin-producing bacteria (actinomyces Streptomyces sp. SA -2581). It is known that they are separated and collected (see Patent Document 1).
- DPPII dipeptidylaminopeptidase II
- Patent Document 1 the physical properties and planar structure of dioctatin are clarified, but 1S is not clarified.
- the structural formula of dioctatin clarified in Patent Document 1 is as shown by the following structural formula (1).
- R represents either hydrogen or a methyl group.
- dioctatin A in which R is a methyl group contains 3 asymmetric carbons
- dioctatin B in which R is hydrogen contains 2 asymmetric carbons.
- Reference 1 shows their absolute structure.
- the secondary metabolites of fungi include useful compounds, but there are many toxic compounds called mycotoxins.
- mycotoxins Currently, contamination of crops with mycotoxins is a serious problem worldwide, and means for controlling mycotoxin contamination are required to stably obtain safe food.
- Aflatoxin is known to have the strongest carcinogenicity among known natural substances, and since it is a compound that cannot be decomposed by ordinary cooking methods, the regulatory value for crop contamination is as low as lOppb. Is provided. For this reason, the amount of damage caused by the destruction of crops contaminated with aflatoxins is also high.
- the method of producing dioctatin by separating and collecting the culture of dioctatin-producing bacteria has problems that the yield of dioctatin may not be stable and the purification process from the culture is not easy. On the other hand, the production method by chemical synthesis was difficult because the absolute structure of dioctatin was revealed.
- Patent Document 2 the present inventors chemically synthesized several stereoisomers based on the planar structure of natural dioctatin obtained from a culture of dioctatin-producing bacteria. The three-dimensional structure of natural dioctatin was clarified by comparing the physical properties of the obtained compounds.
- Patent Document 1 Japanese Patent No. 2966859
- Patent Document 2 Column 2006—015537 Disclosure of the invention
- An object of the present invention is to solve the conventional problems and achieve the following objects.
- the present invention relates to a novel dioctatin derivative, a method for producing the novel dioctatin derivative, and among the novel dioctatin derivatives, DPPII is specifically inhibited, and a novel dioctatin derivative useful as a DPPII inhibitor and aflatoxin production are specifically identified. It is an object of the present invention to provide a novel dioctatin derivative that is effectively and effectively inhibited and useful as an aflatoxin production inhibitor, and further provides a method for controlling aflatoxin contamination using the aflatoxin production inhibitor containing the dioctatin derivative.
- the present invention is based on the above findings by the present inventors, and means for solving the above problems are as follows. That is,
- R and R are CH-(CH)-, (CH) CH- CH-, and C H-CH, respectively.
- n an integer of 2 to 6
- X and X each represent either CH or hydrogen
- Y represents 2-amino-2-butenoic acid or an amino acid residue.
- R and R are both CH (CH) 1, X is a hydrogen atom, and Y is 2
- R and R are CH-(CH)-, (CH) CH- CH-, and C H- CH, respectively.
- n an integer of 2 to 6
- X represents either a hydrogen atom or CH
- X represents a hydrogen atom
- Y represents 2-amino-2-butenoic acid or an amino acid residue.
- R and R are both CH (CH) — and Y is 2-amino-2-butenoic acid
- the amino acid residue is selected from glycine, sarcosine, L-alanine, 13-alanine, L-purin, L-parin, L-leucine, L-phenylalanine, L-thioproline, and 4-hydroxy-L-proline
- a dipeptide compound is synthesized by condensing a compound represented by the following structural formula (b) and an amino acid derivative protected with a carboxyl group,
- R and R are CH-(CH)-, (CH) CH- CH-, and C H- CH, respectively.
- n an integer of 2 to 6
- X and X each represent either CH or hydrogen.
- Q and Q are Boc group, carbobenzoxy group, p-methoxybenzyloxycarbonyl
- Q and Q represent a hydrogen atom.
- a dipeptide compound is synthesized by condensing a compound represented by the following structural formula (a) and a compound represented by the following structural formula (b).
- the tripeptide compound is synthesized by condensation with an amino acid derivative in which the carboxyl group is protected,
- R and R are CH-(CH)-, (CH) CH- CH-, and CH- CH, respectively. Represents one of the
- n an integer of 2 to 6
- X and X each represent either CH or hydrogen.
- Q is any of a Boc group, a carbobenzoxy group, a p-methoxybenzyloxycarbonyl group, an Fmoc group, a 2,2,2-trichloroethoxycarbonyl group, and an aryloxycarbonyl group.
- Q is a hydrogen atom, a methyl group, an ethyl group, a benzyl group, a t-butyl group, and 2, 2, 2—
- ⁇ 6> The method for producing a dioctatin derivative according to any one of ⁇ 4> to ⁇ 5>, wherein the configuration at the 3-position of the structural formula (a) and the structural formula (b) is S.
- the amino acid derivative is any one of glycine, sarcosine, L-alanine, 13-alanine, L-proline, L-noline, L-tipped isine, L-phenylalanine, L-thioproline, and 4-hydroxyl-proline.
- An aflatoxin production inhibitor comprising the dioctatin derivative according to any one of ⁇ 1> to ⁇ 3>.
- R and R are either CH-(CH)-and (CH) CH-CH-, respectively.
- X represents either a hydrogen atom or CH
- n an integer of 2 to 6
- Y represents an amino acid residue
- ⁇ 11> A method for controlling aflatoxin contamination, wherein the aflatoxin production inhibitor according to any one of ⁇ 9> and 10 is used to inhibit aflatoxin production by an aflatoxin-producing bacterium.
- ⁇ 12> The method for controlling aflatoxin contamination according to the above ⁇ 11>, wherein an aflatoxin production inhibitor is administered to a crop and the aflatoxin production of an aflatoxin-producing bacterium infected with the crop is inhibited.
- a conventional problem can be solved, a novel dioctatin derivative, a method for producing the novel dioctatin derivative, a novel dioctatin derivative useful as an aflatoxin production inhibitor, and the dioctatin derivative It is possible to provide a method for controlling aflatoxin contamination using the aflatoxin production inhibitor.
- the dioctatin derivative of the present invention is a compound represented by the following structural formula (I).
- R and R are CH-(CH)-, (CH) CH- CH-, and C H- CH, respectively.
- n an integer of 2 to 6
- X and X each represent either CH or hydrogen
- Y represents 2-amino-2-butenoic acid or an amino acid residue.
- R and R are both CH (CH) and X is a hydrogen atom.
- R and R are CH-(CH)-, (CH) CH- CH-, and C H- CH, respectively.
- n an integer of 2 to 6
- X represents either a hydrogen atom or CH
- X represents a hydrogen atom
- Y represents 2-amino-2-butenoic acid or an amino acid residue.
- R and R are both CH (CH) — and Y is 2-amino-2-butenoic acid.
- the amino acid residue is a force that can be appropriately selected according to the purpose without any particular limitation.
- glycine, sarcosine, L-alanine, 13-alanine, L-proline, L-noline, L-leucine, Residues such as glycine, L-alanine, and L proline are preferred, with residues such as L-ferranin, L thioproline, and 4-hydroxy-l L proline being preferred.
- the dioctatin derivatives represented by the structural formulas (I) and (II) are produced by the method for producing a dioctatin derivative of the present invention described later.
- the dioctatin derivative represented by the structural formulas (I) and (IV) is preferably a physiologically active substance having an activity for inhibiting aflatoxin production.
- the aflatoxin production inhibitor of the present invention contains other components such as a carrier appropriately selected according to the purpose without any particular limitation as long as the dioctatin derivative described in the structural formula (II) is contained as an active ingredient.
- a carrier appropriately selected according to the purpose without any particular limitation as long as the dioctatin derivative described in the structural formula (II) is contained as an active ingredient.
- the dosage form of the aflatoxin production inhibitor can be appropriately selected according to the purpose without any particular restrictions, and includes those formulated with known carriers used for pharmaceuticals and agricultural and horticultural preparations. Examples include solids, powders, tablets, capsules, granules, liquids, gels, creams, and sprays.
- the aflatoxin production inhibitor of the present invention is suitably used for the aflatoxin contamination control method described later.
- Dioctatin derivatives suitable as a component of the aflatoxin production inhibitor include, for example, (S) -3-aminooctanoyl (S) -3-aminooctanoyl L proline, (S ) —3—Aminooctanoyl (S) —3—Aminodecanol and L proline, (S) —3—Aminohexanoyl (L), (S) — 3—Aminooctanoyl leucine (S) —3—Aminooctanoyl leucine (S) —3—Aminooctanoyl leucine (S) —3 —Aminodecanol monoglycine, (S) —3—Aminohexanoyl (S) ) —3—Aminooctanoyl glycine, (S) — 3-Amino 5-methylhexano
- a dioctatin derivative represented by the following structural formula (III) is preferable.
- R and R are CH— (CH 3) — and (CH
- CH— represents either CH—
- X represents either a hydrogen atom or CH
- n represents either a hydrogen atom or CH
- Table 1 below shows examples of preferred U and dioctatin derivatives.
- R, R, X, X, and Y are the same as R, R, X, X in the structural formula (II).
- the method for controlling aflatoxin contamination according to the present invention is a method for inhibiting aflatoxin production by an aflatoxin-producing bacterium using the aflatoxin production inhibitor of the present invention. Any method for administering an inhibitor can be appropriately selected according to the purpose without any particular limitation.
- Examples of the object include plants, agricultural crops, and the like, for example, cereals such as corn, buckwheat and pearl barley, nuts such as peanuts, vistachona nuts, and brazil nuts, Examples include spices such as nutmeg, chili and paprika, and beans such as coffee beans.
- the method for administering the aflatoxin production inhibitor to the target to which the aflatoxin-producing bacterium has adhered or infected can be appropriately selected according to the purpose without any particular limitation. Examples thereof include a method of preparing a pharmaceutical dosage form, and applying, spraying, etc., to an object to which the aflatoxin-producing bacteria adhere or are infected.
- the concentration of the dioctatin derivative in the aflatoxin production inhibitor used in the method for controlling aflatoxin contamination includes the type and breeding of the aflatoxin producing bacteria. It is adjusted as appropriate depending on the degree of, for example, 10-50, OOOppm strength is preferable, and 100-5, OOOppm strength is more preferable! / ⁇ .
- the method for producing a dioctatin derivative of the present invention comprises (1) a first embodiment in which the dioctatin derivative represented by the structural formula ( ⁇ ) is synthesized from the C-terminal side, and (2) the structural formula ( ⁇ ).
- the dioctatin derivative to be synthesized is any one of the second embodiments synthesized from the N-terminal side.
- a dipeptide compound is synthesized by condensing a compound represented by the following structural formula (b) and an amino acid derivative having a carboxyl group protected,
- condensation method and the protecting group removal method can be appropriately selected from known methods without particular limitations.
- R and R are CH-(CH)-, (CH) CH- CH-, and C H-CH, respectively.
- n an integer of 2 to 6
- X and X each represent either CH or hydrogen.
- Q and Q are Boc group, carbobenzoxy group, p-methoxybenzyloxycarbonyl
- Q and Q represent a hydrogen atom.
- an amino acid derivative in which the carboxyl group is protected (for example, amino acid benzyl ester) is added to a compound represented by the structural formula (b) (for example, an N-protected form of 3-aminoalkanoic acid (for example, a 3-amino acid Boc
- the Boc group is removed with TFA or hydrochloric acid ⁇ dioxane, and a compound represented by the structural formula (a) (for example, 3-aminoalkane).
- N-protected acid (for example, 3-amino acid Boc)) is condensed to give a tripeptide benzyl ester, which is protected with a Boc group.
- the amino acid derivative in which the carboxyl group is protected is not particularly limited and can be appropriately selected according to the purpose.
- Examples thereof include amino acid benzyl ester p-toluenesulfonate, and among these, glycine Benzyl ester p-toluene sulfonate, L-alanine benzyl ester p-toluene sulfonate, and L-parin benzyl ester p-toluene sulfonate are preferred.
- the compound represented by the structural formula (a) is not particularly limited and may be appropriately selected depending on the purpose.
- Boc- (S) -3-aminooctanoic acid, Boc- ( S) -3-aminohexanoic acid, Boc (S) -3-amino-5-methylhexanoic acid, and Boc- (2R, 3S) -3 amino-2-methyloctanoic acid are preferred.
- the compound represented by the structural formula (b) is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include Boc- (S) -3-aminooctanoic acid and Boc- (S) -3-aminodecanoic acid is preferred.
- the central amino acid of the tripeptide is a ⁇ -amino acid in the dioctatin derivative, there is no risk of racemization that can occur during normal ⁇ -amino acid peptide synthesis.
- Extending the chain not only the first aspect, but also the heel end zip It can be produced by the second embodiment described below in which a third amino acid is condensed with a peptide.
- a compound represented by the following structural formula (a) and a compound represented by the following structural formula (b) are condensed to synthesize a dipeptide compound.
- a method comprising synthesizing a tripeptide compound by condensing the obtained dipeptide compound and an amino acid derivative with a carboxyl group protected, and removing the protecting group of the obtained tripeptide compound. .
- condensation method and the protecting group removal method can be appropriately selected from known methods without particular limitations.
- R and R are CH-(CH)-, (CH) CH- CH-, and C H- CH, respectively.
- n an integer of 2 to 6
- X and X each represent either CH or hydrogen.
- Q is any of a Boc group, a carbobenzoxy group, a p-methoxybenzyloxycarbonyl group, an Fmoc group, a 2,2,2-trichloroethoxycarbonyl group, and an aryloxycarbonyl group.
- Q is a hydrogen atom, a methyl group, an ethyl group, a benzyl group, a t-butyl group, and 2, 2, 2—
- the compound represented by the structural formula (a) (for example, 3-aminoalkanoic acid ethyl which is an intermediate for producing 3-aminoalkanoic acid (for example, 3-aminodecanoic acid ethyl, 3-aminononanoic acid ethyl, 3-aminoheptanoic acid ethyl, 3-aminoaminohexanoic acid ethyl)) and the structural formula ( b) Condensation with a compound represented by b) (for example, 3-amino acid Boc form), and the resulting Boc dipeptidoethyl ester is conjugated, and then the carboxyl group-protected amino acid derivative (for example, glycine, sarcosine) , L-alanine, L-proline, 13-alanine, etc.), and Boc tripeptide-t-butyl ester is treated with TFA or hydrochloric acid solution in dioxane to form Boc group
- the amino acid derivative in which the carboxyl group is protected is not particularly limited, and can be appropriately selected according to the purpose.
- amino acid t butyl ester hydrochloride and the like are preferred.
- the compound represented by the structural formula (a) is not particularly limited and can be appropriately selected depending on the purpose.
- (S) -3-aminooctanoic acid ethyl ester, and (S) 3-Aminodecanoic acid ethyl ester is preferred!
- the compound represented by the structural formula (b) is not particularly limited and may be appropriately selected depending on the intended purpose.
- Boc- (S) -3-aminooctanoic acid, Boc- ( 2R, 3S) —3 Amino-2-methyloctanoic acid and Boc— (S) -3 aminohexanoic acid are preferred.
- the (2R, 3S) -3 amino-2-methyl otatanyl (S) -3-aminooctanoyl monoglycine was prepared by the following method.
- the reaction solution was concentrated with a rotary evaporator to remove most of the tetrahydrofuran, and then extracted twice with chloroform.
- chloroform solution was dried over anhydrous sodium sulfate and concentrated, a mixture of adduct and excess S—N benzyl 1-phenylethylamine was obtained.
- Dissolve this in hexane inject it into a 200 mL silica gel column packed with hexane, develop with hexane, then hexane ether 50: 3, monitor with UV absorption and detect the first UV absorption coming out.
- the fractions shown were collected and concentrated to yield 6.2 g of adduct.
- the obtained adduct was dissolved in a mixture of water (16 mL), acetic acid (4 mL), and methanol (80 mL), and 10% palladium hydroxide-carbon (880 mg) was reduced at a hydrogen pressure of 40 psi for 16 hours to give 3-aminooctanoic acid. Ethyl ester. The catalyst was removed by filtration, and the residue was concentrated. Then, 60 mL of 4N hydrochloric acid was added and hydrolyzed at 80 ° C. for 16 hours.
- the solution was added alternately with ice-cooling. Stir at room temperature for 1 hour, concentrate under reduced pressure, and add 5% KHSO water.
- Boc- (3S) -3-aminominohexanoic acid was synthesized.
- ⁇ rn ⁇ - ⁇ - ⁇ be, ri, ⁇ ⁇ , ⁇ — ⁇
- Aspergillus parasiticus NRRL2999 was cultured as an aflatoxin-producing bacterium on a potato dextrose agar (PDA medium, Nissui Pharmaceutical Co., Ltd.) slant medium at 27 ° C for 14 days. And spore suspension was prepared by suspending in 0.01% Tween 80 (Sigma) aqueous solution.
- the diluted spore suspension was spread on PDA medium and cultured for 2 days, and the number of colonies that appeared was taken as the number of spores in the suspension.
- Autoclaved PD liquid medium manufactured by DIFCO
- the dioctatin derivative (aflatoxin production inhibitor) obtained in Examples 1, 4, 5, 6, 7, 8, and 12 was added at 0 to 20 ⁇ g / mL.
- N FAST Aflatoxin manufactured by r-biopharm.
- the experiment was performed in triplicate, and the average of the amount of aflatoxin contained in 3 samples of the culture broth obtained by adding inhibitor of each concentration (B), the percentage of inhibition from the amount of aflatoxin without addition (A) [( (A)-(B)) / (A) X 100] was calculated. Calculate the IC value (50% inhibitory concentration) shown in the table based on the% inhibition at each concentration obtained.
- the dioctatin derivative of the present invention has excellent aflatoxin production inhibitory activity in the same manner as that of the natural three-dimensional structure, and in particular, was substituted with glycine obtained in Example 4.
- the dioctatin derivative and the dioctatin derivative substituted with the amino acid residue of L-form obtained in Example 6 and Example 8 were extremely effective in showing an excellent aflatoxin production inhibitory activity.
- the dioctatin derivative of the present invention is useful as an aflatoxin production inhibitor, and can easily inhibit aflatoxin production by administering it to various subjects to which aphatoxin-producing bacteria adhere or are infected.
- the aflatoxin contamination control method of the present invention is particularly suitable for the aflatoxin contamination control method for plants and crops. Is suitable.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0816069A GB2450431B (en) | 2006-02-06 | 2007-02-05 | Method of aflatoxin contamination control using dioctatin derivatives |
JP2007557831A JPWO2007091528A1 (ja) | 2006-02-06 | 2007-02-05 | 新規ジオクタチン誘導体及びその製造方法 |
CA002641520A CA2641520A1 (en) | 2006-02-06 | 2007-02-05 | Novel dioctatin derivatives and process for production thereof |
US12/222,196 US20080312080A1 (en) | 2006-02-06 | 2008-08-05 | Novel dioctatin derivatives and production process thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006028786 | 2006-02-06 | ||
JP2006-028786 | 2006-10-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/222,196 Continuation US20080312080A1 (en) | 2006-02-06 | 2008-08-05 | Novel dioctatin derivatives and production process thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007091528A1 true WO2007091528A1 (ja) | 2007-08-16 |
Family
ID=38345126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/051949 WO2007091528A1 (ja) | 2006-02-06 | 2007-02-05 | 新規ジオクタチン誘導体及びその製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080312080A1 (ja) |
JP (1) | JPWO2007091528A1 (ja) |
CA (1) | CA2641520A1 (ja) |
GB (2) | GB2469959B (ja) |
WO (1) | WO2007091528A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019034934A (ja) * | 2017-08-14 | 2019-03-07 | 学校法人神戸学院 | ペプチド型細菌ジペプチジルペプチダーゼ7阻害剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0377857A (ja) * | 1989-08-22 | 1991-04-03 | Microbial Chem Res Found | 新規生理活性物質ジオクタチン及びその製造方法 |
JPH09241167A (ja) * | 1996-03-04 | 1997-09-16 | Morinaga & Co Ltd | 抗生物質アフラスタチンa又はその塩、それを有効成分とするアフラトキシン汚染防止剤、抗菌剤、抗真菌剤、抗腫瘍剤、及びその製造法 |
JPH1179911A (ja) * | 1997-09-02 | 1999-03-23 | Morinaga & Co Ltd | アフラトキシン汚染防除剤 |
JP2001139507A (ja) * | 1999-08-30 | 2001-05-22 | Morinaga & Co Ltd | 抗生物質ブラストサイジンa誘導体 |
WO2006137297A1 (ja) * | 2005-06-23 | 2006-12-28 | Microbial Chemistry Research Foundation | アフラトキシン生産阻害剤、及びそれを用いたアフラトキシン汚染防除方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2665341B2 (ja) * | 1988-01-11 | 1997-10-22 | オリンパス光学工業株式会社 | 液晶レンズ |
-
2007
- 2007-02-05 CA CA002641520A patent/CA2641520A1/en not_active Abandoned
- 2007-02-05 GB GB1013148A patent/GB2469959B/en not_active Expired - Fee Related
- 2007-02-05 GB GB0816069A patent/GB2450431B/en not_active Expired - Fee Related
- 2007-02-05 JP JP2007557831A patent/JPWO2007091528A1/ja not_active Ceased
- 2007-02-05 WO PCT/JP2007/051949 patent/WO2007091528A1/ja active Application Filing
-
2008
- 2008-08-05 US US12/222,196 patent/US20080312080A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0377857A (ja) * | 1989-08-22 | 1991-04-03 | Microbial Chem Res Found | 新規生理活性物質ジオクタチン及びその製造方法 |
JPH09241167A (ja) * | 1996-03-04 | 1997-09-16 | Morinaga & Co Ltd | 抗生物質アフラスタチンa又はその塩、それを有効成分とするアフラトキシン汚染防止剤、抗菌剤、抗真菌剤、抗腫瘍剤、及びその製造法 |
JPH1179911A (ja) * | 1997-09-02 | 1999-03-23 | Morinaga & Co Ltd | アフラトキシン汚染防除剤 |
JP2001139507A (ja) * | 1999-08-30 | 2001-05-22 | Morinaga & Co Ltd | 抗生物質ブラストサイジンa誘導体 |
WO2006137297A1 (ja) * | 2005-06-23 | 2006-12-28 | Microbial Chemistry Research Foundation | アフラトキシン生産阻害剤、及びそれを用いたアフラトキシン汚染防除方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019034934A (ja) * | 2017-08-14 | 2019-03-07 | 学校法人神戸学院 | ペプチド型細菌ジペプチジルペプチダーゼ7阻害剤 |
JP7228828B2 (ja) | 2017-08-14 | 2023-02-27 | 学校法人神戸学院 | ペプチド型細菌ジペプチジルペプチダーゼ7阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
GB2450431A (en) | 2008-12-24 |
GB0816069D0 (en) | 2008-10-08 |
GB2450431B (en) | 2010-12-15 |
GB2469959A (en) | 2010-11-03 |
GB201013148D0 (en) | 2010-09-22 |
GB2469959B (en) | 2010-12-15 |
US20080312080A1 (en) | 2008-12-18 |
CA2641520A1 (en) | 2007-08-16 |
JPWO2007091528A1 (ja) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5554725A (en) | Synthesis of dolastatin 15 | |
EP2291390A1 (en) | New optically pure compounds for improved therapeutic efficiency | |
US5811400A (en) | Peptide derivatives with δ opioid receptor antagonist or mixed μ agδ antagonist effects | |
CN106117311B (zh) | 一种环肽类化合物及其制备方法和应用 | |
Dahiya et al. | Toward the synthesis and pharmacological screening of a natural cycloheptapeptide of plant origin | |
JPS61197595A (ja) | 胃液分泌を阻害するトリペプチド及びテトラペプチドのエステル,並びに当該成分を活性成分として含む薬剤組成物の製造方法 | |
JP2010155788A (ja) | 新規トリペプチドおよびそれらトリペプチドの製造法、ならびにアンジオテンシン変換酵素阻害物質の製造方法 | |
JP5170608B2 (ja) | アフラトキシン生産阻害剤、及びそれを用いたアフラトキシン汚染防除方法 | |
WO2007091528A1 (ja) | 新規ジオクタチン誘導体及びその製造方法 | |
US8835392B2 (en) | Mimetic peptides and the use thereof in the form of 20S, 26S and immunoproteasome inhibitors | |
JP5456100B2 (ja) | アンジオテンシン変換酵素阻害ジペプチド | |
Hasuoka et al. | Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives I. Structure-activity relationships on the terminal peptidic moiety | |
JP5456144B1 (ja) | アンジオテンシン変換酵素阻害ジペプチド | |
WO2020022892A1 (en) | Tubulysin derivatives and methods for preparing the same | |
Tatsumi et al. | Evaluation of retro-inverso modifications of HTLV-1 protease inhibitors containing a hydroxyethylamine isoster | |
JP4490547B2 (ja) | 新規ペプチド、その製造法及び用途 | |
JPH0578290A (ja) | ホモキラルα−アミノアルデヒドのジアステレオ選択的な還元的ピナコールカツプリング法 | |
CN100412082C (zh) | 环糖基氨基酸及其制备方法和防治重金属中毒的用途 | |
Malipeddi et al. | Synthesis, anhelmintic, antimicrobial and anti-inflammatory activities of axinastatin-3 | |
US20100063150A1 (en) | Aflatoxin Production Inhibitor and Method for Controlling Aflatoxin Contamination Using the Same | |
WO2011051071A1 (en) | 2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides such as bacitracins | |
JPH07145084A (ja) | Tan−1511関連化合物 | |
JPH07233084A (ja) | 化学療法剤効果増強剤 | |
Ding | Total synthesis of didemnin B analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007557831 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2641520 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 0816069 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20070205 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0816069.9 Country of ref document: GB |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07708067 Country of ref document: EP Kind code of ref document: A1 |